CTI BioPharma Corp. (CTIC)

CTI BioPharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Net Income	-69.24	-92.99	-97.91	-52.45	-40.02	-29.4
Depreciation & Amortization	2.15	1.95	0.53	0.53	0.55	0.59
Share-Based Compensation	10.85	10.03	4.74	4.32	5.17	6.37
Other Operating Activities	-26.08	-0.18	7.75	5.4	6.49	-17.47
Operating Cash Flow	-82.32	-81.19	-84.89	-42.21	-27.82	-39.82
Capital Expenditures	0	0	0	-0.02	0	-0.03
Acquisitions	-25	-25	0	0	0	0
Change in Investments	-33.6	-48.85	12	-9.6	28.13	-30.46
Investing Cash Flow	-58.6	-73.85	12	-9.62	28.13	-30.49
Share Issuance / Repurchase	63.66	63.31	57.03	66.63	0	64.22
Debt Issued / Paid	6.48	58.72	41.33	-5.33	-5.33	-0.44
Other Financing Activities	-1.92	-2	-0.41	-0.22	-0.28	-0.29
Financing Cash Flow	68.22	120.02	97.94	61.07	-5.61	63.49
Net Cash Flow	-72.69	-35.03	25.05	9.25	-5.3	-6.78
Free Cash Flow	-82.32	-81.19	-84.89	-42.22	-27.82	-39.86
Free Cash Flow Margin	-108.64%	-150.50%	-	-	-831.75%	-151.61%
Free Cash Flow Per Share	-0.63	-0.71	-0.94	-0.59	-0.48	-0.71

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).